105
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Development and Validation of Prognostic Nomograms for Elderly Patients with Osteosarcoma

, , &
Pages 5581-5591 | Published online: 14 Sep 2021

References

  • Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–234. doi:10.1002/ijc.24320
  • Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2017;13:357–368. doi:10.2217/fon-2016-0261
  • Simpson E, Brown HL. Understanding osteosarcomas. JAAPA. 2018;31:15–19. doi:10.1097/01.JAA.0000541477.24116.8d
  • Khandekar S, Dive A, Munde P, Fande PZ. Chondroblastic osteosarcoma of the left zygomatic bone: rare case report and review of the literature. J Oral Maxillofac Pathol. 2014;18:281–285. doi:10.4103/0973-029X.140791
  • Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer-Am Cancer Soc. 2003;97:3068–3075.
  • Gao Z, Zhou S, Song H, Wang Y, He X. Nomograms for predicting overall survival and cancer-specific survival of chondroblastic osteosarcoma patients. J Surg Oncol. 2020;122:1676–1684. doi:10.1002/jso.26185
  • Tempelaere C, Biau D, Babinet A, Anract P. Osteosarcoma after the age of fifty: a clinicopathological study. Eur J Surg Oncol. 2019;45:1288–1292. doi:10.1016/j.ejso.2019.04.010
  • Tsuchie H, Emori M, Nagasawa H, et al. Prognosis of primary osteosarcoma in elderly patients: a comparison between young and elderly patients. Med Princ Pract. 2019;28:425–431. doi:10.1159/000500404
  • Wang Z, Wu B, Zhou Y, et al. Predictors of the survival of primary and secondary older osteosarcoma patients. J Cancer. 2019;10:4614–4622. doi:10.7150/jca.32627
  • Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–1370. doi:10.1200/JCO.2007.12.9791
  • He Y, Liu H, Wang S, Zhang J. A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy. Sci Rep. 2020;10:12817. doi:10.1038/s41598-020-69740-2
  • Chen H, Liu J, Cheng Z, et al. Development and external validation of an MRI-based radiomics nomogram for pretreatment prediction for early relapse in osteosarcoma: a retrospective multicenter study. Eur J Radiol. 2020;129:109066. doi:10.1016/j.ejrad.2020.109066
  • Wu G, Zhang M. A novel risk score model based on eight genes and a nomogram for predicting overall survival of patients with osteosarcoma. BMC Cancer. 2020;20:456. doi:10.1186/s12885-020-06741-4
  • Zhang J, Xu J, Jin S, Gao W, Guo R, Chen L. The development and validation of a nomogram for predicting brain metastases in lung squamous cell carcinoma patients: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. J Thorac Dis. 2021;13:270–281. doi:10.21037/jtd-20-3494
  • Zhu X, Huang R, Hu P, et al. Prognostic factors for survival in patients with malignant giant cell tumor of bone: a risk nomogram analysis based on the population. Med Sci Monit. 2021;27:e929154.
  • Battersby NJ, Bouliotis G, Emmertsen KJ, et al. Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score. Gut. 2018;67:688–696.
  • Pan X, Yang W, Chen Y, Tong L, Li C, Li H. Nomogram for predicting the overall survival of patients with inflammatory breast cancer: a SEER-based study. Breast. 2019;47:56–61. doi:10.1016/j.breast.2019.05.015
  • Xiong Y, Cao H, Zhang Y, et al. Nomogram-predicted survival of breast cancer brain metastasis: a SEER-based population study. World Neurosurg. 2019;128:e823–e834. doi:10.1016/j.wneu.2019.04.262
  • Yu C, Zhang Y. Development and validation of prognostic nomogram for young patients with gastric cancer. Ann Transl Med. 2019;7:641. doi:10.21037/atm.2019.10.77
  • Chen S, Liu Y, Yang J, et al. Development and validation of a nomogram for predicting survival in male patients with breast cancer. Front Oncol. 2019;9:361. doi:10.3389/fonc.2019.00361
  • Sun HH, Chen XY, Cui JQ, Zhou ZM, Guo KJ. Prognostic factors to survival of patients with chondroblastic osteosarcoma. Medicine. 2018;97:e12636. doi:10.1097/MD.0000000000012636
  • Eric I, Petek EA, Koprivcic I, Babic M, Pacaric S, Trogrlic B. Independent factors FOR poor prognosis in young patients with stage I-III breast cancer. Acta Clin Croat. 2020;59:242–251.
  • Lian W, Fu F, Lin Y, et al. The impact of young age for prognosis by subtype in women with early breast cancer. Sci Rep. 2017;7:11625. doi:10.1038/s41598-017-10414-x
  • Hagleitner MM, Hoogerbrugge PM, van der Graaf WT, et al. Age as prognostic factor in patients with osteosarcoma. Bone. 2011;49:1173–1177. doi:10.1016/j.bone.2011.08.014
  • Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–3035. doi:10.1200/JCO.2014.59.4895
  • Janeway KA, Barkauskas DA, Krailo MD, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group. Cancer-Am Cancer Soc. 2012;118:4597–4605.
  • Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790. doi:10.1200/JCO.2002.20.3.776
  • Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol. 2014;21:263–268. doi:10.1245/s10434-013-3210-4
  • Manoso MW, Healey JH, Boland PJ, et al. De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy. Clin Orthop Relat Res. 2005;438:110–115. doi:10.1097/01.blo.0000179587.42350.4d
  • Nishida Y, Isu K, Ueda T, et al. Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group. J Surg Oncol. 2009;100:48–54. doi:10.1002/jso.21287
  • Fan XL, Cai GP, Zhu LL, Ding GM. Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. Drug Des Devel Ther. 2015;9:5925–5932. doi:10.2147/DDDT.S91217
  • Jiang Y, Wang T, Wei Z. Construction and validation of nomograms for predicting the prognosis of juvenile osteosarcoma: a real-world analysis in the SEER database. Technol Cancer Res Treat. 2020;19:1079215366. doi:10.1177/1533033820947718
  • Hayakawa K, Matsumoto S, Ae K, et al. Definitive surgery of primary lesion should be prioritized over preoperative chemotherapy to treat high-grade osteosarcoma in patients aged 41–65 years. J Orthop Traumatol. 2020;21:13. doi:10.1186/s10195-020-00552-w
  • Grimer RJ, Cannon SR, Taminiau AM, et al. Osteosarcoma over the age of forty. Eur J Cancer. 2003;39:157–163. doi:10.1016/S0959-8049(02)00478-1